Breast cancer prognostic factors/pathobiology

乳腺癌预后因素/病理学

基本信息

批准号：
7483769
负责人：
KATHLEEN E MALONE
金额：
$ 79.71万
依托单位：
FRED HUTCHINSON CANCER RESEARCH CENTER
依托单位国家：
美国
项目类别：
财政年份：
2004
资助国家：
美国
起止时间：
2004-09-15 至 2011-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7483769
关键词：
Address Affect Age Age-Years Ancillary Study Biology Blood Body Size Body Weight Changes Breast Cancer Prognostic Factor CDKN1A gene Cancer Etiology Cell Cycle Proteins Cessation of life Characteristics Clinical Clinical Trials Cohort Studies Cyclin D1 Cyclin E DNA Data Diagnosis Diagnostic Disease Disease Progression Enrollment Facility Construction Funding Category Family history of Follow-Up Studies Foundations Future Goals Grant Hormones Incidence Interview Invasive Investigation Medical Records Molecular Numbers Pathology Patients Persons Pharmaceutical Preparations Phase Physical activity Pliability Ploidies Population Prognostic Marker Recurrence Reproductive History Resources Risk Risk Factors Staging TP53 gene Telephone Interviews Testing Time Tissue Microarray Tissues Tumor Markers Woman age group aged base breast cancer diagnosis cohort follow-up insight malignant breast neoplasm mortality older women oncoprotein p21 outcome forecast p27 Cell Cycle Protein p27 Enzyme Inhibitor response tumor tumor progression

项目摘要

DESCRIPTION (provided by applicant): Breast cancer mortality is the second leading cause of cancer death in women. In spite of improvements in stage and advances in treatment, mortality from breast cancer continues to be substantial and there exists a paucity of insights regarding factors that influence disease progression and mortality. In particular, little is known about how patient and tumor characteristics relate to mortality in middle- and older aged women. We propose to conduct a population-based molecular-epidemiologic cohort study of factors that predict mortality in women diagnosed with invasive breast cancer at ages 45 through 79. The overall goal of the study is to evaluate patient and tumor characteristics for their relationship with the risk of breast cancer mortality. The proposed cohort consists of 2337 women diagnosed with a first invasive breast cancer at 45-79 years of age during the period 1993-1999, all of whom previously completed an extensive interview regarding exposures prior to diagnosis and will now be followed for mortality. Telephone interviews and medical record reviews will be used to collect information on exposures after diagnosis, disease recurrences, and treatment details. Tumor characteristics and markers will be assessed in relation to both mortality and patient factors as a basis for understanding determinants of prognosis. The aims of this study are: (1) to determine if patient characteristics and exposures (before and after diagnosis), including some which are potentially modifiable, are related to the risk of dying from breast cancer, (2) to determine if patient characteristics and exposures prior to diagnosis are associated with histopathologic features and tumor markers, (3) to assess the relationship of histopathologic factors and tumor markers, including both well characterized prognostic markers and less well-characterized cell cycle proteins, with the risk of dying from breast cancer, (4) to build tissue microarrays that will allow rapid assessment of future markers as they are identified, (5) to build a comprehensive resource for future ancillary studies. The investigation of tumor and patient characteristics in relation to mortality could provide etiologic and clinical insights regarding determinants of prognosis and help to generate clues regarding the biology of breast cancer progression.

描述（由申请人提供）：乳腺癌死亡率是女性癌症死亡的第二大原因。尽管阶段有所改善和治疗进展，但乳腺癌的死亡率仍然很大，并且对影响疾病进展和死亡率的因素的见解很少。特别是，关于患者和肿瘤特征与中年妇女的死亡率如何相关的知之甚少。我们建议对45至79岁诊断患有侵入性乳腺癌的女性的死亡率进行基于人群的分子流行病学研究研究。该研究的总体目标是评估患者和肿瘤特征与乳腺癌风险的关系。死亡。拟议的队列由1993 - 1999年期间45-79岁的2337名妇女组成，该妇女在45-79岁时被诊断出患有首次侵入性乳腺癌，所有这些妇女以前曾在诊断前接受了有关暴露的广泛采访，现在将遵循死亡率。电话访谈和病历审查将用于收集有关诊断后的暴露，疾病复发和治疗细节的信息。将根据死亡率和患者因素来评估肿瘤特征和标志物，以此作为理解预后决定因素的基础。这项研究的目的是：（1）确定患者特征和暴露（诊断前后）（包括一些可能修改的可能性）是否与乳腺癌死亡的风险有关，（2）确定患者特征和诊断前的暴露于诊断前的患者特征和暴露，是否与组织病理学特征和肿瘤标记物相关，包括较少的特征和肿瘤标志物，（3），（3）均与Historapics Markers的关系相关，（3）特征良好的细胞周期蛋白具有死于乳腺癌的风险，（4）建立组织微阵列，可以在确定的未来标记中快速评估未来的标记，（5）为未来的辅助研究建立全面的资源。肿瘤和患者特征与死亡率有关的研究可以提供有关预后决定因素的病因和临床见解，并有助于产生有关乳腺癌进展的生物学的线索。